Clinical trials versus registries in coronary revascularization: Which are more relevant?

Current Opinion in Cardiology

Volumn 22, Issue 6, 2007, Pages 524-528

  Mack, Michael J ^a,b  

^a Cardiopulmonary Research Science and Technology Institute   (United States)

^b NONE   (United States)

Author keywords

Coronary artery bypass surgery; Observational databases; Percutaneous coronary intervention; Randomized controlled trials

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; DATA BASE; DEATH; EXTERNAL VALIDITY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INFORMATION; META ANALYSIS; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; PRIORITY JOURNAL; REGISTER; REVIEW; RISK ASSESSMENT; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; HUMANS; MYOCARDIAL REVASCULARIZATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES;

EID: 35148898782     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f078e3     Document Type: Review

References (29)

1. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344:1117-1124.
2. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass graft surgery versus stent implantation. N Engl J Med 2005; 352:2174-2183.
3. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents in Sweden. N Engl J Med 2007; 356:1009-1019. This presents results of the Swedish National Registry on stent therapy, which tracks every stent placed in Sweden. This observational database showed a risk-adjusted increase in mortality at 3 years with drug-eluting stents compared with bare metal stents.
4. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356:1030-1039. A meta-analysis of randomized trials shows that survival and myocardial infarction are the same with drug-eluting and bare metal stents.
5. Mauri L, Hsieh W, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020-1029. A meta-analysis of stent trials shows no difference in stent thrombosis between bare metal and drug-eluting stents.
6. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomized controlled trial. Lancet 2002; 360:965-970.
7. Rodriguez A, Bernardi V, Navia J, et al. Argentine Randomized Study:Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. J Am Coll Cardiol 2001; 37:51-58.
8. Hueb W, Soares PR, Gersh BJ, et al. The Medicine, Angioplasty, or Surgery Study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease. J Am Coll Cardiol 2004; 43:1743-1751.
9. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. J Am Coll Cardiol 2001; 38:143-149.
10. Berger PB, Velianou JL, Aslanidou Vlachos H, et al. Survival following coronary angioplasty versus coronary artery bypass surgery in anatomic subsets in which coronary artery bypass surgery improves survival compared with medical therapy. Results from the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 2001; 38:1440-1449.
11. Kurbaan AS, Bowker TJ, Rickards AF. Differential restenosis rate of individual coronary artery sites after multivessel angioplasty: implications for revascularization strategy. CABRI Investigators. Coronary Angioplasty versus Bypass Revascularization Investigation. Am Heart J 1998; 135:703-708.
12. King SB, Lembo NJ, Weintraub WS, et al. A randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST). N Engl J Med 1994; 331:1044-1050.
13. Weintraub WS, Mauldin PD, Becker E, et al. A comparison of costs and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995; 92:2831-2840.
14. Rodriguez A, Mele E, Peyregne E, et al. Three-year followup of the Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease (ERACI). J Am Coll Cardiol 1996; 27:1178-1184.
15. Hamm CW, Reimers J, Ischinger T, et al. A randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI). N Engl J Med 1994; 331:1037-1043.
16. Stroupe KT, Douglass AM, Hlatky MA, et al., the AWESOME investigators. Cost-Effectiveness of Coronary Artery Bypass Grafts Versus Percutaneous Coronary Intervention for Revascularization in High-Risk Patients. Circulation 2006; 114:1251-1257. This landmark trial is different from previous trials in that it randomized high-risk patients for intervention.
17. Pocock SJ, Henderson RA, Rickards AF, et al. Meta-analysis of randomized trials comparing coronary angioplasty with bypass surgery. Lancet 1995; 346:1184-1189.
18. Mercado N, Wijns W, Serruys PW, et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials. J Thorac Cardiovasc Surg 2005; 130: 512-519.
19. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one to eight year outcomes. J Am Coll Cardiol 2003; 41:1293-1304.
20. Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007; 297:1992-2000. An analysis of observational registry data indicated that results outside of trials differ from trial results.
21. Hordijk-Trion M, Lenzen M, Wijns W, et al., on behalf of the EHS-CR Investigators. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur Heart J 2006; 27:671-678. A survey indicated that results in clinical trials are not externally valid to 'real-world' clinical practice.
22. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48:2584-2591. Observational data first raised the issue of stent thrombosis not seen in randomized trials.
23. Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 2006; 144:913-919. This is an in-depth analysis of trials and trial design.
24. Kappetein AP, Dawkins KD, Mohr FW, et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease: Insights from the SYNTAX run-in phase. Eur J Cardio Thorac Surg 2006; 29:486-491.
25. Boden WE, O'Rourke RA, Teo KK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516. This randomized trial demonstrated that as an initial strategy optimal medical therapy is as effective as PCI.
26. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109:2290-2295.
27. Malenka DJ, Leavitt BJ, Hearne MJ, et al. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation 2005; 112:371-376.
28. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006; 82:1420-1429. Results from the Duke database: the authors analyzed the results in all strata of risk of patients undergoing CABG and PCI.
29. Guyton RA. Coronary artery bypass is superior to drug-eluting stents in multivessel coronary artery disease. Ann Thorac Surg 2006; 81:1949-1951. This is an editorial review of the treatments and results of CABG and PCI in multivessel disease.